Home › Funds › BARCLAYS PLC › ABT
BARCLAYS PLC position in ABT
ABBOTT LABORATORIES · Health Care
BARCLAYS PLC reported holding 3,863,474 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$350.6M, representing 0.40% of its reported portfolio and ranking #48 among its reported holdings. BARCLAYS PLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BARCLAYS PLC's ABT position evolved
BARCLAYS PLC first disclosed a stake in ABT in Q3 2023 at 10,000 shares (US$968K). The position peaked in Q2 2026 at 3,863,474 shares, worth US$350.6M. Across 12 filings, BARCLAYS PLC increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,863,474 shares valued at US$350.6M — an increase of 3,803,474 shares quarter over quarter.. Notable position changes include a 804% increase in Q4 2024 (shares rose 18% over the following quarter), a 1349% increase in Q4 2025 (shares fell 18% over the following quarter), a 6339% increase in Q2 2026 (shares rose 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 10.00K | $968.50K | New |
| Q4 2023 | 9.60K | $1.06M | Reduce |
| Q1 2024 | 48.00K | $5.46M | Add |
| Q2 2024 | 409.60K | $42.56M | Add |
| Q3 2024 | 5.60K | $638.46K | Reduce |
| Q4 2024 | 50.60K | $5.72M | Add |
| Q1 2025 | 76.30K | $10.12M | Add |
| Q2 2025 | 29.90K | $4.07M | Reduce |
| Q3 2025 | 30.10K | $4.03M | Add |
| Q4 2025 | 436.10K | $54.64M | Add |
| Q1 2026 | 60.00K | $6.16M | Reduce |
| Q2 2026 | 3.86M | $350.57M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABT and 13F data
ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABT
- Vanguard Group 175.56M sh · $22.00B · Q4 2025
- Charles Schwab Investment Management 59.67M sh · $5.41B · Q2 2026
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC 59.67M sh · $5.41B · Q2 2026
- Sixth Street Partners Management Company, L.P. 59.67M sh · $5.41B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital Research Global Investors 36.91M sh · $3.35B · Q2 2026
- Capital International Investors 34.65M sh · $3.15B · Q2 2026
- Deutsche Bank AG 16.71M sh · $1.52B · Q2 2026
More on BARCLAYS PLC
FAQ
How long has BARCLAYS PLC held ABT?
BARCLAYS PLC has disclosed ABT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BARCLAYS PLC's current position in ABT?
As of Q2 2026, BARCLAYS PLC holds 3.86M shares of ABT (ABBOTT LABORATORIES), valued at $350.57M, representing 0.40% of its reported portfolio and ranking #48.
Has BARCLAYS PLC been buying or selling ABT?
In the latest 13F filing (Q2 2026), BARCLAYS PLC increased its position in ABT. The position peaked in Q2 2026 at 3.86M shares.
Which other funds hold ABT?
Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.